Breast cancer patients with vitamin D deficiency needed more pain medicine and reported more moderate pain after mastectomy — a suggestive link, though the study can’t prove cause and effect.
Up to 1 in 5 people with high blood pressure may have a hormone disorder that standard daytime blood tests overlook — because the telltale hormone surges mostly at night.
Definium’s DT120 eased generalized anxiety in a second large Phase 3 study — positioning the company to seek what would be the first-ever approval of a psychedelic medicine for anxiety.
A pioneer of donor-derived cell therapy is walking away from cancer CAR-T — battered by competition — and pivoting to in vivo gene editing for heart disease. Investors sent the stock down 43%.
A red-light photodynamic treatment with Biofrontera’s Ameluz gel is now approved for superficial basal cell carcinoma — the first photodynamic therapy okayed for any skin cancer.
Crohn’s patients ate the same plant foods as healthy controls and had more oxalate in their stool. The difference was in the transporters, not the diet.
Wall-mounted sensors processing on-device rather than in the cloud. The architecture choice is what makes the product legally and practically deployable.
Menstrual changes, chills, hot flashes. Nobody asked these patients — which is exactly why the answers are interesting, and why they prove nothing.
The survey finding is real. So is the fact that it was commissioned by an organisation that advocates plant-based diets — and the underlying evidence is genuinely mixed.
Olivia and Tom Walton have committed an initial $100M to Healthy Moms, Healthy Babies America. The money is small next to the problem — which is exactly why it is structured as matching capital.
Semaglutide started at the mouse equivalent of late middle age added about 100 days of life and improved memory, muscle and blood sugar. The animals were neither obese nor diabetic — which is what makes the result interesting.
The phase 3 LONESTAR trial tested a widely assumed strategy — radiate or resect what remains after checkpoint blockade — and found no survival benefit, not even in the oligometastatic patients it was supposed to help most.